Sangamo Biosciences (SGMO) Misses Q2 EPS by 4c

Sangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $14.72 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• SentinelOne, Inc. (S) Tops Q2 EPS by 1c; offers guidance
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook